ProShare Advisors
CAPR icon

ProShare Advisors’s Capricor Therapeutics CAPR Stock Holding History

ProShare Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,033
Closed -$203K – 1891
2025
Q4 		$203K Buy
+7,033
New +$91.8K ﹤0.01% 1712
2025
Q1 		– Sell
-10,317
Closed -$142K – 2117
2024
Q4 		$142K Buy
+10,317
New +$181K ﹤0.01% 1987

Other funds holding CAPR

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
JHC
Jones Hill Capital New York $470M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ProShare Advisors's CAPR Position: Q1 2026 in Review

ProShare Advisors sold out of Capricor Therapeutics (CAPR) in Q1 2026, closing a stake of 7,033 shares — an estimated $203K sold.

ProShare Advisors first reported a position in CAPR in Q4 2024 and held it in 2 quarters. The position peaked at $203K in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • ProShare Advisors reported no remaining Capricor Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ProShare Advisors sold 7,033 Capricor Therapeutics shares in Q1 2026, an estimated $203K.
  • ProShare Advisors first reported a position in Capricor Therapeutics in Q4 2024 and held it in 2 quarters.
  • ProShare Advisors's Capricor Therapeutics position peaked at $203K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.